Literature DB >> 3534695

Post lung-stage schistosomula of Schistosoma mansoni exhibit transient susceptibility to macrophage-mediated cytotoxicity in vitro that may relate to late phase killing in vivo.

E J Pearce, S L James.   

Abstract

Studies of protective immunity against Schistosoma mansoni in immunized mice suggest that a proportion of challenge parasites may be eliminated after they have passed through the lungs of the host several days after infection; however, no potential immune effector mechanism of resistance against this stage of the parasite has yet been identified, since schistosomes have been shown to rapidly become resistant to antibody-dependent killing mechanisms. In this study, different development stages of S. mansoni were examined for their susceptibility to in vitro cytotoxicity by lymphokine-activated macrophages. As previously shown, newly transformed larvae were readily killed by lymphokine-treated peritoneal macrophages or the macrophage cell line IC-21 (80% mortality over 48 h in vitro), whereas 7 and 10 day old lung-stage parasites had become refractory to macrophage effects. However, after 2 to 2 1/2 weeks of development in vivo, juvenile parasites recovered from the liver were again susceptible to activated macrophage-mediated cytotoxicity (25-65% mortality). Ultrastructural studies of 2 1/2 week old parasites co-cultured with activated IC-21 cells revealed that damage was largely restricted to the areas beneath the parasite surface and gut syncitia; surface membrane disruption was not evident. This late stage of susceptibility was transient and by 4 to 6 weeks liver-stage worms had again become refractory to macrophage killing. The interaction of post lung-stage parasites with activated macrophages was antibody independent. Furthermore, schistosomes isolated from the portal circulation 2 1/2 weeks after infection showed no evidence of surface-bound immunoglobulin in a quantitative immunofluorescence assay, nor did antisera from chronically infected mice (CIS) or mice vaccinated with irradiated cercariae (VS) react with the surface of these parasites in vitro, making the possibility of direct antibody-dependent killing mechanisms unlikely. However, both CIS and VS did recognize excretory/secretory proteins synthesized by 2 1/2 week old liver-stage schistosomes, including a major antigen of approximate Mr (X 10(-3] 220 (220K). It is therefore possible that such antigens might participate in protective immunity, for example via immune complex formation or activation of sensitized T cells. These observations support the role of macrophages as immune effector cells in mice immunized against Schistosoma mansoni, and provide the first physiologically relevant mechanism whereby the immune system might recognize and kill post-lung stage schistosomes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3534695     DOI: 10.1111/j.1365-3024.1986.tb00866.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  17 in total

1.  Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models.

Authors:  Workineh Torben; Gul Ahmad; Weidong Zhang; Afzal A Siddiqui
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

2.  Impaired immunity and altered pulmonary responses in mice with a disrupted interferon-gamma receptor gene exposed to the irradiated Schistosoma mansoni vaccine.

Authors:  R A Wilson; P S Coulson; C Betts; M A Dowling; L E Smythies
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

3.  Activated macrophages as effector cells of protective immunity to schistosomiasis.

Authors:  S L James
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

4.  Cytostatic and cytotoxic effects of activated macrophages and nitric oxide donors on Brugia malayi.

Authors:  G R Thomas; M McCrossan; M E Selkirk
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

5.  Genetic association of defects in macrophage larvicidal activity and vaccine-induced resistance to Schistosoma mansoni in P strain mice.

Authors:  S L James; R Correa-Oliveira; A Sher; L A Medvitz; R D McCall
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

6.  Schistosoma mansoni larvicidal activity of murine bronchoalveolar lavage cells.

Authors:  F A Lewis; C A White-Ziegler; J E Ball; G M Niemann
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

7.  Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the adult worm stage.

Authors:  Rosemary M Cook; Claudia Carvalho-Queiroz; Gregory Wilding; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Role of antibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection against Schistosoma mansoni.

Authors:  Workineh Torben; Gul Ahmad; Weidong Zhang; Stewart Nash; Loc Le; Souvik Karmakar; Afzal A Siddiqui
Journal:  Vaccine       Date:  2012-09-20       Impact factor: 3.641

9.  Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen.

Authors:  E J Pearce; S L James; S Hieny; D E Lanar; A Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

10.  Schistosomiasis.

Authors:  F Lewis
Journal:  Curr Protoc Immunol       Date:  2001-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.